Appian, an innovative global provider of business process management (BPM) technology, announced today that the U.S. Food and Drug Administration (FDA) has selected the award-winning Appian Enterprise BPM Suite as its platform of choice for the development of process-centric applications. The FDA, the scientific regulatory agency responsible for protecting and advancing the public health in the United States, chose Appian’s comprehensive BPM Suite in support of a strategic vision to transform FDA operations in response to emerging scientific, technological, and economic trends affecting its regulatory mission. This transformational vision reflects the principles of productivity and accountability embodied in the President’s Management Agenda and the e-Government initiative. The three-year contract totals $797,000.
Using BPM technology, FDA expects to provide more accurate and timely data with which to make decisions that directly affect its core duties. Additionally, the time and money saved using Appian will allow a greater opportunity to enhance services to the various FDA centers.
The U.S. Food and Drug Administration’s more than 10,000 scientific, technical, and support staff effect the lives of every American every day. Consumers spend nearly $1.5 trillion each year on FDA-regulated products, which represents over 20 percent of all consumer expenditures. The FDA believes that developing a process-centric approach to IT development will provide improved support in advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health. Efficiencies will be realized in better response times from IT, consistent development practices and artifacts produced from projects, and a reduced effort to manage total contractor teams. By providing standard reference architecture, development practices, tools, and examples through reference implementation, the FDA will be able to transform its IT practices into a holistic approach that better-serves the enterprise and the public.
“BPM is fundamentally changing the way government agencies operate,” said Matthew Calkins, President and CEO of Appian. “Viewing application development as an agency-wide effort instead of each individual center managing their own practices will improve the coordination and orchestration of how IT supports the FDA’s mission.”
About the U.S. Food and Drug Administration (FDA)
The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods to improve their health.
About Appian
Appian is the BPM pure-play expert. Appian leads the market in BPM innovation, delivering comprehensive, flexible and easy-to-use solutions customized to the unique needs of individual organizations. Businesses and governments worldwide use Appian to simplify process innovation with the real-time visibility, control and analytics needed to improve the critical processes that determine business performance. Appian allows all users across the organization to effectively collaborate and be part of the process of achieving corporate goals. Appian is backed by the premier venture firm Novak Biddle Venture Partners, and is headquartered in the Washington D.C. region, with professional services and partners around the globe. For more information, visit www.appian.com.
For Information Contact: Ben Farrell Director, Corporate Communications +1 703.442.1067 Email Contact
SOURCE: Appian Corporation
Comments